CSIMarket
 
Keenova Therapeutics Plc  (MNK)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 40
 Employees 1,600
 Revenues (TTM) (Millions $) 1,413
 Net Income (TTM) (Millions $) -573
 Cash Flow (TTM) (Millions $) 82
 Capital Exp. (TTM) (Millions $) 150

Business Description


Mallinckrodt Plc is a specialty pharmaceutical company that develops and manufactures a wide range of medical products used in the treatment of rare and critical diseases.

The company was founded in 1867 and is headquartered in Dublin, Ireland, with its primary commercial offices located in the United States. With a rich history of over 150 years, Mallinckrodt has become a leading provider of medical products and services in the healthcare industry, serving millions of patients worldwide.

The company's pharmaceutical products cover a range of areas, including pain management, autoimmune and rare diseases, respiratory disorders, and central nervous system disorders. Mallinckrodt is known for producing specialty drugs such as Acthar Gel, a drug used in the treatment of autoimmune disorders, and Ofirmev, an intravenous acetaminophen injection used for pain management in hospitals.

In addition to pharmaceutical products, Mallinckrodt also produces medical devices and diagnostics tools. The company's medical devices line includes products such as surgical instruments, single-use catheters, and implantable devices for spine and orthopedics. Its diagnostics business offers various imaging agents and injectable dyes used in radiology and cardiology procedures.

Mallinckrodt's operations span over 40 countries, with manufacturing facilities located in the Americas, Europe, and Asia. The company employs over 4,500 people and maintains strong partnerships with healthcare providers and researchers.

Mallinckrodt has a strong commitment to social responsibility and sustainability. The company has implemented green initiatives to reduce its environmental footprint, such as carbon emissions reduction targets, waste diversion programs, and water conservation efforts. Furthermore, the company supports various community outreach programs, including those focused on education, health, and the environment.

Overall, Mallinckrodt is a reputable and innovative pharmaceutical company known for its high-quality products and commitment to improving patient care. Its dedication to social responsibility and sustainability has also garnered the company a positive reputation in the healthcare industry.


   Company Address: College Business & Technology Park Dublin 15
   Company Phone Number: 696 0000   Stock Exchange / Ticker: MNK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.38% 
PFE        1.75% 
REGN        4.22% 
TEVA   -0.22%    
VRTX        0.82% 
VTRS        3.3% 
• View Complete Report
   





Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.29
Working Capital Ratio 3.01
Leverage Ratio (MRQ) 1.8
Total Debt to Equity 1.3
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -19.47 $
Revenues (TTM) 35.68 $
Cash Flow (TTM) 2.06 $
Cash 20.83 $
Book Value 49.45 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 883,125
Net Income per Employee (TTM) -358,188
Receivable Turnover Ratio (TTM) 3.12
Inventory Turnover Ratio (TTM) 1.09
Asset Turnover Ratio (TTM) 0.25

Profitability Ratios Current
Gross Margin (MRQ) 39.91 %
Operating Margin (MRQ) -14.33 %
Net Margin (MRQ) -24.27 %
Net Cash Flow Margin (MRQ) 2.5 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Keenova Therapeutics Plc's Segments
Rebates and Chargebacks    41.7 % of total Revenue
Product Returns    1.39 % of total Revenue
Other Sales Deductions    1.05 % of total Revenue
Transferred at Point in Time    0 % of total Revenue
Transferred over Time    0 % of total Revenue
Acthar Gel    36.25 % of total Revenue
Xiaflex    28.74 % of total Revenue
INOmax    12.57 % of total Revenue
Amitiza    4.49 % of total Revenue
Other Products    16.83 % of total Revenue
License Revenue    1.26 % of total Revenue
Single Reportable    210.76 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.